GTBP
GT Biopharma Inc
NASDAQ: GTBP · HEALTHCARE · BIOTECHNOLOGY
$0.31
+13.31% today
Updated 2026-04-30
Market cap
$8.83M
P/E ratio
—
P/S ratio
204.96x
EPS (TTM)
$-6.68
Dividend yield
—
52W range
$0 – $4
Volume
0.7M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.3
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$3.00
+873.39%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-4.02M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-20.88M | $-7.60M | $-13.16M | $-28.35M | $-23.03M |
| EPS | — | — | — | — | $-6.68 |
| Free cash flow | $-15.22M | $-8.85M | $-12.90M | $-12.91M | $-4.02M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
GT Biopharma Inc trades at $0.31. Our Smart Value Score of 31/100 indicates the stock is weak.
Frequently asked questions
What is GT Biopharma Inc's stock price?
GT Biopharma Inc (GTBP) trades at $0.31.
Is GT Biopharma Inc overvalued?
Smart Value Score 31/100 (Grade F, Strong Sell).
What is the price target of GT Biopharma Inc (GTBP)?
The analyst target price is $3.00, representing +873.4% upside from the current price of $0.31.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio204.96x
ROE-1,377.00%
Beta1.20
50D MA$0.43
200D MA$0.82
Shares out0.03B
Float0.03B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—